Hi everyone, We hope you have seen our announcement regarding...

Hi everyone,

We hope you have seen our announcement regarding the first patient enrolled in our Phase I HER2 breast cancer study. You can read the full announcement here.

This ground-breaking study investigates the use of a MagSense® imaging agent as a means of aiding in the staging of HER2 positive breast cancer by detecting if the patient’s tumor has spread to the lymph nodes. With the first patient now enrolled and multiple sites participating we look forward to getting more enrolments soon.

Join us in our 2021 Annual General Meeting later this week to hear more. You can join virtually, with this link https://web.lumiagm.com/324289675.